The results below are discovered through our pilot algorithms. Let us know how we are doing!
- 1. Shurbaji MS, Kuhajda FP, Pasternack GR, Thurmond TS. Expression of oncogenic antigen 519 (OA‐519) in prostate cancer is a potential prognostic indicator. Am J Clin Pathol. 1992;97:686-691.
- 2. Epstein JI, Carmichael M, Partin AW. OA‐519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology. 1995;45:81-86.
- 3. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. Increased fatty acid synthase as a therapeutic target in androgen‐independent prostate cancer progression. Prostate. 2001;47:102-110.
- 4. Pizer ES, Thupari J, Han WF, et al. Malonyl‐coenzyme‐A is a potential mediator of cytotoxicity induced by fatty‐acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 2000;60:213-218.
- 5. Zhou W, Simpson PJ, McFadden JM, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res. 2003;63:7330-7337.
- 6. Rae C, Haberkorn U, Babich JW, Mairs RJ. Inhibition of fatty acid synthase sensitizes prostate cancer cells to radiotherapy. Radiat Res. 2015;184:482-493.
- 7. Thupari JN, Kim EK, Moran TH, Ronnett GV, Kuhajda FP. Chronic C75 treatment of diet‐induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass. Am J Physiol Endocrinol Metab. 2004;287: E97-E104.
- 8. Aja S, Landree LE, Kleman AM, et al. Pharmacological stimulation of brain carnitine palmitoyl‐transferase‐1 decreases food intake and body weight. Am J Physiol Regul Integr Comp Physiol. 2008;294:R352-R361.
- 9. Bentebibel A, Sebastián D, Herrero L, et al. Novel effect of C75 on carnitine palmitoyltransferase I activity and palmitate oxidation. Biochemistry. 2006;45:4339-4350.
- 10. Mera P, Bentebibel A, López‐Viñas E, et al. C75 is converted to C75‐CoA in the hypothalamus, where it inhibits carnitine palmitoyltransferase 1 and decreases food intake 2009;77:1084-1095.
- 11. Makowski K, Mera P, Paredes D, et al. Differential pharmacologic properties of the two C75 enantiomers: (+)‐C75 is a strong anorectic drug; (-)‐C75 has antitumor activity. Chirality. 2013;25:281-287.
- 12. Sadowski MC, Pouwer RH, Gunter JH, Lubik AA, Quinn RJ, Nelson CC. The fatty acid synthase inhibitor triclosan: repurposing an anti‐microbial agent for targeting prostate cancer. Oncotarget. 2014;5:9362-9381.
- 13. Relat J, Blancafort A, Oliveras G, et al. Different fatty acid metabolism effects of (-)‐epigallocatechin‐3‐gallate and C75 in adenocarcinoma lung cancer. BMC Cancer. 2012;12:280.
- 14. Mims J, Bansal N, Bharadwaj MS, et al. Energy metabolism in a matched model of radiation resistance for head and neck squamous cell cancer. Radiat Res. 2015;183:291-304.
- 15. McNeely W, Benfield P. Orlistat. Drugs. 1998;56:241-249.
No related research data.
No similar publications.